secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001062822-23-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon Q4 net loss $30.5M; NDA for sotagliflozin on track for May PDUFA
------------------------------------------------------------------------

- Net loss $30.5M ($0.16 per share) vs $25.6M ($0.17) in Q4 2021; full-year loss $101.9M ($0.62).
- R&D expenses $14.0M (down from $16.5M); SG&A $16.3M (up from $8.8M) due to launch prep.
- Cash and investments $138.4M as of Dec 31, 2022, up from $86.7M year-end 2021.
- Sotagliflozin NDA for heart failure on track for May 2023 PDUFA date after FDA late-cycle review.
- LX9211 showed consistent results in diabetic neuropathic pain; PHN study missed primary endpoint (p=0.12) but showed evidence of effect.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282223000004/0001062822-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282223000004/lxrx-20230302.htm
  HTML page:      https://secwatch.observer/filing/0001062822-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer